Could a common antioxidant boost chemo for advanced lung cancer?
NCT ID NCT07574684
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding alpha lipoic acid (a strong antioxidant) to standard chemotherapy helps people with advanced non-small cell lung cancer. About 60 adults with stage III or IV lung cancer will take 600 mg of alpha lipoic acid daily alongside their chemo. Researchers will measure tumor response, survival, and quality of life to see if this combination improves outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart cancer therapy: tailoring lung cancer treatment with a simple blood test
- New drug cocktail targets tough lung cancer
- Blood test could speed up lung cancer treatment decisions
- New drug duo takes on advanced lung cancer
- Lung cancer surgery risks under the microscope: 1,000 patients studied
- New study aims to crack the code on cancer drug resistance